European Journal of Medical Research (Jun 2024)

Inflammation accelerating intestinal fibrosis: from mechanism to clinic

  • Shuzi Xin,
  • Xiaohui Liu,
  • Chengwei He,
  • Han Gao,
  • Boya Wang,
  • Rongxuan Hua,
  • Lei Gao,
  • Hongwei Shang,
  • Fangling Sun,
  • Jingdong Xu

DOI
https://doi.org/10.1186/s40001-024-01932-2
Journal volume & issue
Vol. 29, no. 1
pp. 1 – 25

Abstract

Read online

Abstract Intestinal fibrosis is a prevalent complication of IBD that that can frequently be triggered by prolonged inflammation. Fibrosis in the gut can cause a number of issues, which continue as an ongoing challenge to healthcare systems worldwide. The primary causes of intestinal fibrosis are soluble molecules, G protein-coupled receptors, epithelial-to-mesenchymal or endothelial-to-mesenchymal transition, and the gut microbiota. Fresh perspectives coming from in vivo and in vitro experimental models demonstrate that fibrogenic pathways might be different, at least to some extent, independent of the ones that influence inflammation. Understanding the distinctive procedures of intestinal fibrogenesis should provide a realistic foundation for targeting and blocking specific fibrogenic pathways, estimating the risk of fibrotic consequences, detecting early fibrotic alterations, and eventually allowing therapy development. Here, we first summarize the inflammatory and non-inflammatory components of fibrosis, and then we elaborate on the underlying mechanism associated with multiple cytokines in fibrosis, providing the framework for future clinical practice. Following that, we discuss the relationship between modernization and disease, as well as the shortcomings of current studies. We outline fibrosis diagnosis and therapy, as well as our recommendations for the future treatment of intestinal fibrosis. We anticipate that the global review will provides a wealth of fresh knowledge and suggestions for future fibrosis clinical practice. Graphical Abstract

Keywords